BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), an industry leader in prenatal clinical laboratory testing, announced that it now offers Integrated screening and Sequential screening tests under license from Intema Limited. When Integrated screening and Sequential screening test results include a fetal ultrasound nuchal translucency measurement, the highest Down syndrome detection rates are achieved and fewer false positives are experienced than with current first- or second-trimester screening. In January 2007, the American College of Obstetricians and Gynecologists issued a Practice Bulletin recommending that regardless of age, all pregnant women be offered screening for Down syndrome, and ideally, be offered screening that combines first- and second-trimester screening. Subsequently, LabCorp announced an agreement with Intema, Ltd. to license its technology for combining first and second trimester Down syndrome screening test results.
